The effect of combining antibiotics on resistance: A systematic review and meta-analysis

Berit Siedentop[1,2*], Viacheslav N. Kachalov[2,3], Christopher Witzany[1], Matthias Egger[4,5,6], Roger D. Kouyos[2,3†], Sebastian Bonhoeffer[1*†]

[1] Institute of Integrative Biology, Department of Environmental Systems Science, ETH Zürich, Zurich, Switzerland

[2] Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zürich, University of Zürich, Zürich, Switzerland

[3] Institute of Medical Virology, University of Zurich, Zurich, Switzerland

[4] Institute of Social and Preventive Medicine (ISPM), University of Bern, Bern, Switzerland

[5] Population Health Sciences, University of Bristol, Bristol, UK

[6] Centre for Infectious Disease Epidemiology and Research, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa

[†]These authors contributed equally

*Berit Siedentop, Sebastian Bonhoeffer

Email: berit.siedentop@env.ethz.ch, seb@env.ethz.ch

Author Contributions: SB, RDK, VNK, and BS conceived and designed the study. RDK and SB supervised the project. BS was responsible for the design of the literature search and the study protocol. VNK, RDK, SB, and ME reviewed the study protocol and approved it. VNK, CW, BS conducted the literature review, performed the data extraction. CW and BS assessed the quality of the studies. RDK, SB and BS conceptualised the statistical analysis. BS analysed the data. BS wrote the initial draft of the manuscript, which was revised by ME, RDK, CW and SB. All authors reviewed and approved the final version of the manuscript.

Competing Interest Statement: We declare no competing interests.

Keywords: antibiotic resistance, resistance evolution, combination therapy, meta-analysis, systematic review

Abstract

When and under which conditions antibiotic combination therapy decelerates rather than accelerates resistance evolution is not well understood. We examined the effect of combining antibiotics on within-patient resistance development across various bacterial pathogens and antibiotics.

We searched CENTRAL, EMBASE and PubMed for (quasi)-randomised controlled trials (RCTs) published from database inception to November 24th, 2022. Trials comparing antibiotic treatments with different numbers of antibiotics were included. A patient was considered to have acquired resistance if, at the follow-up culture, a resistant bacterium was detected that had not been present in the baseline culture. We combined results using a random effects model and performed meta-regression and stratified analyses. The trials' risk of bias was assessed with the Cochrane tool.

42 trials were eligible and 29, including 5054 patients, were qualified for statistical analysis. In most trials, resistance development was not the primary outcome and studies lacked power. The combined odds ratio (OR) for the acquisition of resistance comparing the group with the higher number of antibiotics with the comparison group was 1.23 (95% CI 0.68-2.25), with substantial between-study heterogeneity (I^2=77%). We identified tentative evidence for potential beneficial or detrimental effects of antibiotic combination therapy for specific pathogens or medical conditions.

The evidence for combining a higher number of antibiotics compared to fewer from RCTs is scarce and overall, is compatible with both benefit or harm. Trials powered to detect differences in resistance development or well-designed observational studies are required to clarify the impact of combination therapy on resistance.

Main Text

Introduction

Antibiotics are one of the most significant advances in modern medicine, prescribed to treat various bacterial infections in both humans and animals and prevent infections, such as surgical site infections or opportunistic infections in immunocompromised individuals(1). However, this medical breakthrough is at risk due to the rising prevalence of antibiotic resistance and an inadequate pipeline of new antibiotics. This disturbing trend threatens to undermine the effectiveness of antibiotics and poses a severe challenge to public health worldwide.(2, 3) Hence, we need a more prudent use of antibiotics, and where antibiotics are needed, we need treatment strategies that reduce the risk that resistance emerges or spreads. Different strategies for the

64 optimal use of antibiotics have been investigated theoretically and empirically.(4-7) Antibiotic
65 combination therapy, i.e., the simultaneous administration of several antibiotics, is frequently
66 discussed as a promising strategy for avoiding resistance evolution.(6-10) Importantly, it is the
67 standard of care for some bacterial pathogens, such as *H. pylori*, *Mycobacterium tuberculosis*
68 (Mtb), or *Mycobacterium leprae*.(11-13). However, it is unclear whether the effect of combination
69 therapy on resistance is consistent for different pathogens.

70 There are several motivations for the use of antibiotic combination therapy, including to
71 broaden the antibiotic spectrum in empirical treatment and reducing antibiotic resistance
72 development.(14, 15) The simultaneous occurrence of resistance mutations to multiple drugs is
73 less likely than resistance to single drugs. Combination therapy should, therefore, reduce the
74 development of resistance.(10) This expectation is supported by viral infections such as HIV,
75 where multiple point mutations are required for resistance to combination antiviral therapy.
76 However, it is less clear to what extent this reasoning extends to antibiotic therapy, where the
77 same mechanism can facilitate bacterial survival against multiple antibiotics,(16, 17) and where
78 horizontal transfer of resistance may occur. Indeed, the benefit of combining antibiotics for
79 reducing resistance is debated for bacterial infections.(18) Using more antibiotics overall could
80 lead to more resistance, as overall antibiotic consumption correlates with resistance.(19)

81 Two meta-analyses of randomised controlled trials (RCTs) comparing beta-lactam
82 monotherapy to beta-lactam and aminoglycoside combination therapy found no differences in
83 resistance development.(4, 5) However, the effect of combining antibiotics on within-patient
84 resistance development across many bacterial pathogens and various antibiotic combinations
85 has not been addressed. Even though within-patient antibiotic resistance development is rare, it
86 may contribute to the emergence and spread of resistance. We performed a systematic review
87 and meta-analysis to (i) test the effect of antibiotic combination therapy on within-patient
88 resistance development and (ii) evaluate which factors affect the performance of combination
89 therapy, as e.g. pathogen identity, treatment design and resistance assessment.

90 **Results**
91
92 The search identified 3082 articles, which decreased to 1837 after deduplication. A total of 488
93 studies were eligible for full-text review, of which 41 studies qualified for inclusion. The screening
94 of the citations of the 41 studies identified one additional eligible study, for a total of 42 studies,
95 40 RCTs and two quasi-RCTs (figure 1, table 1).(20-61) Twenty-nine studies could be included in
96 the meta-analysis; 13 were excluded due to zero events in both treatment arms.

97 The included studies were published between 1977 and 2021, with a median publication
98 year of 1995 and few recent studies (figure 2 A). The development of antibiotic resistance was

typically not the main outcome: only nine studies (21%) explicitly defined a resistance outcome (SI p 6). Consequently, most studies did not have the statistical power to detect a large effect on within-patient resistance development (figure 2 B, SI p 14). Twenty-two (52%) focused on a specific pathogen species (resistant *Acinetobacter baumannii*, *Escherichia coli*, *H. pylori*, Mtb, methicillin-resistant *Staphylococcus aureus* (MRSA), *Pseudomonas aeruginosa*, *Staphylococcus aureus*) or pathogen group (MAC, *Salmonella enterica* subsp. *enterica* serotype Thyphi, or *Salmonella enterica* subsp. *enterica* serotype Parthypi A).

The five most frequent reasons for antibiotic administration were treatment or prophylaxis of urinary tract infections (UTIs) (6 studies, 14%), MRSA (5 studies, 12%), *H.* pylori, MAC, and prophylaxis for blood cancer patients with four studies (10%) respectively. Twenty-three of the included studies (55%) compared treatment arms that with at least one administered antibiotic in common; the remaining studies compared treatment arms with no overlap in administered antibiotics (table 1). For the outcome acquisition of resistance, only two of all 42 studies had a low overall risk of bias according to the risk of bias assessment. Twelve (29%) were at high risk of bias, 28 (67%) at moderate risk of bias (SI p 3).

The overall pooled OR for acquisition of resistance comparing a lower number of antibiotics versus a higher one was 1.23 (95% CI 0.68 – 2.25), with substantial heterogeneity between studies (I^2 =77.4%). The latter OR was compatible with the OR for *de novo* emergence of resistance (pooled OR 0.74, 95% CI 0.34 – 1.59; I^2=77%). Since the results for the two resistance outcomes are comparable, our focus in the following is on the acquisition of resistance (details on emergence of resistance can be found in the SI p 2, p 4, p 8).

Stratified analyses revealed that a higher number of antibiotics performed better than a lower number in case of *H. pylori*, (pooled OR 0.14, 95% CI 0.03 – 0.55; I^2 =41.7%, figure 2A), and *MAC* (pooled OR 0.18, 95% CI 0.06 – 0.52; I^2 =26.8%, figure 2A), but worse in case of *P. aeruginosa* (pooled OR 3.42, 95% CI 1.03 – 11.43; I^2=1.54%, figure 2A). Furthermore, a lower number of antibiotics performed better than a higher number if the compared treatment arms had no antibiotics in common (pooled OR 4.73, 95% CI 2.14 – 10.42; I^2=37%, SI p 7). In contrast, when restricting the analysis to studies with at least one common antibiotic in the treatment arms are pooled there was little evidence of a difference (pooled OR 0.55, 95% CI 0.28 – 1.07; I^2 =74%, figure 3B). When considering only resistance measurements of antibiotics common to both treatment arms instead of all resistance measurements, the arm with a higher number of antibiotics shows a benefit in comparison to the one with fewer (pooled OR 0.39, 95% CI 0.18 – 0.81; I^2=75%, SI p 6). If the study measured the acquisition of resistance of both gram negative and positive bacteria, fewer antibiotics performed better (pooled OR 3.38, 95% CI 1.08 – 10.58;

133 I^2=38.35%, SI p 5). Other sub-group analyses did not show any harm or benefit of using a higher
134 number of antibiotics. The results for all subgroup analyses are presented in the supplement (SI p
135 4). The multi-model inference for our meta-regression showed that the only significant factor
136 influencing the outcome acquisition of resistance is whether at least one common antibiotic was
137 used in the comparator arms (for details see SI p 8).

138 The inspection of the funnel plot and the modified Egger's test showed no indication of a
139 publication bias (SI p 4). The results were largely robust to the choice of the random effects
140 model (SI p 8). The probability of the secondary outcome "alterations of the prescribed treatment
141 due to adverse events", was higher using more antibiotics in comparison to fewer (pooled OR
142 1.61, 95% CI 1.12 – 2.31; I^2=5%; SI p 10). In 15 studies (36%), the proportion of patients with
143 alterations of the prescribed treatment due to adverse events was reported, with three studies
144 (20%) reporting zero cases in both treatment arms. All other analyses of secondary outcomes
145 showed no indication of harm or benefit of treating with a higher number of antibiotics (SI p 9).

146 **Discussion**
147
148 We performed a meta-analysis of RCTs and quasi-RCTs not limited to a particular
149 bacterial species, specific condition, or antibiotic combinations to assess the effect of antibiotic
150 combination therapy on within-patient resistance development. Our analysis could not identify any
151 benefit or harm of using a higher or a lower number of antibiotics regarding within-patient
152 resistance development. However, we found some evidence that combining antibiotics may be
153 beneficial or harmful for specific pathogens or infection types. Acquisition of resistance was rarely
154 a primary objective of the included RCTs. Hence, they were typically not designed to detect
155 differences in resistance development between treatment arms and underpowered for this
156 endpoint. Therefore, the absence of evidence does not mean that there is convincing evidence
157 for the lack of an effect of using more or fewer antibiotics on resistance development but rather
158 highlights a knowledge gap. This is remarkable given that the general rise of resistance is an
159 increasing concern(18, 62) and a priority area for health policy and public health.(63)

160 Our analysis showed that combining antibiotics reduced resistance development for *H.*
161 *pylori* or MAC, in line with the current standard of care.(11, 64) Surprisingly, we found only two
162 studies that satisfied our inclusion criteria for Mtb(24, 40), which may be considered the prime
163 example of effective antibiotic combination therapy. The limited number of Mtb studies may be
164 because antibiotic administration commonly varies during Mtb treatment, which conflicted with our
165 inclusion criteria that necessitated a consistent treatment regimen for susceptibility
166 measurements (see SI, page 2). Both eligible Mtb studies were excluded from the analysis due to
167 the absence of any events in either treatment arm.

168 Our main result, the absence of a general effect of combining antibiotics on resistance
169 development, aligns with the two previous meta-analyses.(4, 5) With 42 trials in our systematic
170 review and 29 in the meta-analysis, our study provided a comprehensive assessment of the effect
171 of antibiotic combination therapy on within-patient resistance. Whereas previous meta-analyses
172 focused on a combination of specific antibiotic classes and included fewer than ten studies each,
173 our study aimed to assess the general effect of combining antibiotics on resistance evolution
174 across different bacterial pathogens. By including trials with different antibiotic combinations and
175 bacterial pathogens, we increased clinical and statistical heterogeneity. We accounted for many
176 sources of heterogeneity using stratification and meta-regression, but analyses were limited by
177 missing information and sparse data.

178 Our findings have implications for the design of future studies of resistance development.
179 Generally, the development of resistance within a patient is a rare event. However, even small
180 differences could be relevant at the population level. To obtain reliable estimates of such
181 differences and to better understand the factors influencing them, very large RCTs would be
182 needed, which systematically investigate the development of antibiotic resistance and include
183 resistance testing of each administered antibiotic. To better evaluate the effect of combination
184 therapy, especially more RCTs would be needed where the basic antibiotic treatment is
185 consistent across both treatment arms, i.e. the antibiotics used in both treatment arms should be
186 identical, except for the additional antibiotic added in the comparator arm (figure 3). As such
187 RCTs are costly and associated with high hurdles, the analysis of cohort studies could be an
188 alternative approach. Over 25 years ago, Fish et al. published a systematic summary of
189 prospective observational studies reporting data on resistance development, including antibiotic
190 combination therapy.(65) Similarly, today, relevant cohort studies could be analysed
191 collaboratively using various modern statistical methods to address confounding by indication and
192 other biases(66, 67).

193 The main strength of this study is its comprehensive and systematic approach. For one, it
194 allowed identifying a knowledge gap regarding the effect of antibiotic combination therapy on
195 resistance development. Further, our study highlights several issues in the evidence base
196 evaluating antibiotic combination therapy and resistance development. The included trials did not
197 always test for susceptibility against all administered antibiotics (table 1). Some antibiotics might
198 have had reduced potency or were ineffective due to pre-existing resistance mutations.
199 Furthermore, in studies where treatment was not targeted against a specific pathogen, some
200 antibiotics may have been inactive against the causative pathogen due to intrinsic resistance.
201 Indeed, one of the reasons for using combination therapy is to broaden the bacterial spectrum for
202 empirical therapy(15), which could contribute to an increased risk of antibiotic resistance spread.

Our study had several limitations. First, despite our systematic search, we might have missed relevant studies. Since resistance development is typically not a primary endpoint and often not reported systematically, relevant trials are challenging to identify. Our search strategy aimed to identify a broad range of trials considering resistance development. However, as a trade-off, our search strategy might have missed trials addressing a specific medical condition or drug combination. Second, our systematic review and meta-analysis included many older studies that did not follow the relevant reporting guidelines(68), thereby hampering data extraction and potentially introducing bias. Third, it is often challenging to discern the specific mechanisms by which resistance develops based on the data from clinical trials. This includes distinguishing whether resistance arises *de novo*, if the pathogen acquires resistance through horizontal gene transfer, if the patient becomes newly infected with a resistant pathogen, or if the pathogen was present but undetected at the beginning of treatment. These scenarios can impact the effectiveness of combination therapy. For example, combination therapy may be more likely to select any pre-existing resistant pathogens compared to monotherapy due to the use of multiple antibiotics. We addressed some of this heterogeneity by employing two different measures of resistance (see SI, page 2). Furthermore, the variation in standards that classify bacteria as susceptible or resistant adds another layer of heterogeneity alongside the technical limitations in detecting resistance development.

In conclusion, combination therapy offers potential advantages and disadvantages regarding resistance evolution and spread. On the one hand, combination therapy typically increases the genetic barrier to resistance, and it has become the standard therapy for pathogens notorious for resistance evolution. Therefore, combination therapy remains a plausible candidate strategy to slow down resistance evolution. On the other hand, combination therapy generates selection pressure for resistance to multiple antibiotics simultaneously and could, therefore, accelerate resistance evolution – especially in the microbiome. Given the critical nature of this context, it is profoundly disconcerting that there is a lack of evidence elucidating the impact of combining antibiotics on the development of resistance

Materials and Methods

Inclusion criteria and search strategy

We did a systematic review and meta-analysis to summarise the evidence on the effect of antibiotic combination therapy on resistance development. We included RCTs and quasi-RCTs comparing treatments with a higher number of antibiotics to treatments with a lower number of antibiotics. Studies were classified as quasi-RCTs if the allocation of participants to study arms was not truly random. We did not consider antiseptics or compounds supporting the activity of

238 antibiotics, such as beta-lactam inhibitors as antibiotics itself. Whereas the antibiotic substances
239 administered within one treatment arm had to be the same for all patients, the antibiotics could
240 differ between treatment arms. We required baseline and follow-up cultures with resistance
241 measurements to determine the treatment impact on resistance. We considered only antibiotic
242 treatment regimens fixed for the period between two resistance measurements. Hence, we
243 excluded sequential and cycling regimens.

244 We searched PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials
245 (CENTRAL) from inception up to 24.11.2022, using keywords, medical subject headings (MeSH),
246 and EMTREE terms related to bacterial infection, antibiotics, combination therapy, resistance and
247 RCTs. We excluded complementary and alternative medicine and bismuth. The search strategy
248 is detailed in the SI (p 26). After a systematic deduplication process,(69) VNK (or CW) and BS
249 independently screened the titles and abstracts, and, if potentially eligible, the full texts. Any
250 discrepancies between VNK (or CW) and BS were discussed and resolved. At full-text screening,
251 we excluded articles that were not accessible in English or German. We screened the references
252 of eligible studies and the trials included in two previous meta-analyses.(4, 5) We followed the
253 PRISMA reporting guidelines(70) and registered our protocol with PROSPERO
254 (CRD42020187257).

255

256 **Outcomes**

257 We used two definitions for the primary outcome resistance. A broader definition, "acquisition of
258 resistance", and a stricter "*de novo* emergence of resistance" definition, where the latter is a
259 subset of the former. A patient was considered to have acquired resistance if, at the follow-up
260 culture a resistant bacterium was detected that was not present in the baseline culture. *De novo*
261 emergence of resistance was defined as the detection of a resistant bacterium that was present
262 at baseline but sensitive. Additional secondary outcomes included mortality from all causes and
263 infection, treatment failure overall, treatment failure due to resistance, treatment change due to
264 adverse effects, and acquisition/*de novo* emergence of resistance against non-administered
265 antibiotics. The SI (p 2, p 18) provides further details.

266 **Data extraction and analysis**

267 VNK (or CW) and BS independently extracted all study data using a standardised form (see
268 https://osf.io/gwefy/?view_only=f6a4c1f4c79241038b203bd03c8e1845). The data extracted
269 included the proportion of patients who developed the two primary outcomes and the secondary
270 outcomes and study characteristics such as type of trial (RCT or quasi-RCT), follow-up and

treatment duration, number of antibiotics in the treatment arms, type of antibiotic, and presence of comorbidities. Any discrepancies in data extraction were discussed and resolved.

We calculated odds ratios (ORs) with 95% confidence intervals (CIs), comparing a higher with a lower number of antibiotics for each study. We combined ORs using a modified version of the Simmonds and Higgins random effects model.(71) If a study had more than two eligible treatment arms, they were merged for statistical analysis. Studies with zero events in both treatment arms were excluded from the statistical analysis. We used subgroup analyses and meta-regressions with multi-model inference to examine the influence of pre-specified variables on summary ORs. Variables included whether the antibiotic(s) used in the arm with the lower number of antibiotics are also part of the arm(s) with the higher number of antibiotics, the number of antibiotics administered, the age of the antibiotics (time since market entry), the administration of other non-antibiotic drugs, whether participants had specific comorbidities or were in intensive care, gram-status of the tested pathogens, and the length of antibiotic treatment and follow-up. We extended our predefined analysis regarding the reason for antibiotic treatment/type of pathogen, which was initially restricted to only *H. pylori* and Mtb, as we found enough studies to stratify by other conditions/pathogens. We furthermore performed post-hoc subgroup analyses to examine the following factors: treatment of resistant pathogens, additional antibiotic administration besides the fixed treatment, and the way of antibiotic administration (SI p 14).

Between study heterogeneity was estimated with I^2, using the criteria for I^2 specified in Higgins et al. for classifying the degree of heterogeneity.(72) CW and BS assessed each study's quality for the main outcomes using the Risk of Bias tool (RoB 2, SI p 7).(73) To assess publication bias, we visually inspected the funnel plot and a modified Egger's test (SI p 10). We performed sensitivity analyses on the model choice (SI p 8), and risk of bias (SI p 9), and performed a post-hoc trial sequential analysis (SI p 17). Statistical analyses and visualisations were done in R (version 4.2.1) using packages *metafor* and *MuMIn*.(74, 75)

Acknowledgments

Support from the Swiss National Science Foundation (grant 310030B_176401 (SB, BS, CW), grant 32FP30-174281 (ME), grant 324730_207957 (RDK)) and from the National Institute of Allergy and Infectious Diseases (NIAID, cooperative agreement AI069924 (ME)) is gratefully acknowledged. We thank Anthony Hauser, João Pires and Frédérique Lachmann for helpful discussions and Annelies Zinkernagel and Johannes Nemeth for critical reading of the manuscript. Furthermore, we are grateful for all contacted study authors that responded to our inquiries and provided further information.

References

307 1. Taplitz RA, Kennedy EB, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial
308 Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical
309 Practice Guideline Update. Journal of Clinical Oncology. 2018;36(30):3043-54.
310 2. Hutchings MI, Truman AW, Wilkinson B. Antibiotics: past, present and future. Current
311 Opinion in Microbiology. 2019;51:72-80.
312 3. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden
313 of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet.
314 2022;399(10325):629-55.
315 4. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of
316 Aminoglycoside and β-Lactam Combination Therapy versus β-Lactam Monotherapy on the
317 Emergence of Antimicrobial Resistance: A Meta-analysis of Randomized, Controlled Trials.
318 Clinical Infectious Diseases. 2005;41(2):149-58.
319 5. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy
320 versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane
321 Database of Systematic Reviews. 2014(1).
322 6. Angst DC, Tepekule B, Sun L, Bogos B, Bonhoeffer S. Comparing treatment strategies to
323 reduce antibiotic resistance in an in vitro epidemiological setting. Proceedings of the National
324 Academy of Sciences. 2021;118(13):e2023467118.
325 7. Tepekule B, Uecker H, Derungs I, Frenoy A, Bonhoeffer S. Modeling antibiotic treatment
326 in hospitals: A systematic approach shows benefits of combination therapy over cycling, mixing,
327 and mono-drug therapies. PLOS Computational Biology. 2017;13(9):e1005745.
328 8. Sullivan GJ, Delgado NN, Maharjan R, Cain AK. How antibiotics work together: molecular
329 mechanisms behind combination therapy. Current Opinion in Microbiology. 2020;57:31-40.
330 9. Tyers M, Wright GD. Drug combinations: a strategy to extend the life of antibiotics in the
331 21st century. Nature Reviews Microbiology. 2019;17(3):141-55.
332 10. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic
333 resistance. Proceedings of the National Academy of Sciences. 1997;94(22):12106-11.
334 11. De Francesco V, Bellesia A, Ridola L, Manta R, Zullo A. First-line therapies for
335 Helicobacter pylori eradication: a critical reappraisal of updated guidelines. Ann Gastroenterol.
336 2017;30(4):373-9.
337 12. Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on
338 drug resistance in Mycobacterium tuberculosis. Journal of Applied Microbiology.
339 2020;128(6):1547-67.
340 13. Alemu Belachew W, Naafs B. Position statement: LEPROSY: Diagnosis, treatment and
341 follow-up. Journal of the European Academy of Dermatology and Venereology.
342 2019;33(7):1205-13.
343 14. Pletz MW, Hagel S, Forstner C. Who benefits from antimicrobial combination therapy?
344 The Lancet Infectious Diseases. 2017;17(7):677-8.
345 15. Roemhild R, Bollenbach T, Andersson DI. The physiology and genetics of bacterial
346 responses to antibiotic combinations. Nature Reviews Microbiology. 2022.
347 16. Du D, Wang-Kan X, Neuberger A, van Veen HW, Pos KM, Piddock LJV, et al. Multidrug
348 efflux pumps: structure, function and regulation. Nature Reviews Microbiology. 2018;16(9):523-
349 39.
350 17. Lázár V, Snitser O, Barkan D, Kishony R. Antibiotic combinations reduce Staphylococcus
351 aureus clearance. Nature. 2022;610(7932):540-6.

352 18. Holmes AH, Moore LSP, Sundsfjord A, Steinbakk M, Regmi S, Karkey A, et al.
353 Understanding the mechanisms and drivers of antimicrobial resistance. The Lancet.
354 2016;387(10014):176-87.
355 19. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in
356 Europe and association with resistance: a cross-national database study. The Lancet.
357 2005;365(9459):579-87.
358 20. Bender JF, Schimpff SC, Young VM, Fortner CL, Brouillet MD, Love LJ, et al. Role of
359 vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in
360 leukemic patients. Antimicrobial agents and chemotherapy. 1979;15(3):455-60.
361 21. Black RE, Levine MM, Clements ML, Cisneros L, Daya V. Treatment of experimentally
362 induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-
363 sulfamethoxazole, or placebo. Reviews of infectious diseases. 1982;4(2):540-5.
364 22. Chaisson RE, Keiser P, Pierce M, Fessel WJ, Ruskin J, Lahart C, et al. Clarithromycin and
365 ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium
366 complex disease in patients with HIV infection. AIDS (London, England). 1997;11(3):311-7.
367 23. Cometta A, Baumgartner JD, Lew D, Zimmerli W, Pittet D, Chopart P, et al. Prospective
368 randomized comparison of imipenem monotherapy with imipenem plus netilmicin for
369 treatment of severe infections in nonneutropenic patients. Antimicrobial agents and
370 chemotherapy. 1994;38(6):1309-13.
371 24. Dawson R, Diacon AH, Everitt D, van Niekerk C, Donald PR, Burger DA, et al. Efficiency
372 and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during
373 the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial
374 in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (london,
375 england). 2015;385(9979):1738-47.
376 25. Dekker AW, Rozenberg-Arska M, Verhoef J. Infection prophylaxis in acute leukemia: a
377 comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Annals of internal
378 medicine. 1987;106(1):7-11.
379 26. Dickstein Y, Lellouche J, Schwartz D, Nutman A, Rakovitsky N, Dishon Benattar Y, et al.
380 Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs.
381 Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.
382 Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
383 2019.
384 27. Dubé MP, Sattler FR, Torriani FJ, See D, Havlir DV, Kemper CA, et al. A randomized
385 evaluation of ethambutol for prevention of relapse and drug resistance during treatment of
386 Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy.
387 Journal of Infectious Diseases. 1997;176(5):1225-32.
388 28. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al.
389 Colistin and rifampicin compared with colistin alone for the treatment of serious infections due
390 to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial.
391 Clinical infectious diseases. 2013;57(3):349-58.
392 29. Fournier S, Burguière AM, Flahault A, Vincent V, Treilhou MP, Eliaszewicz M. Effect of
393 adding clofazimine to combined clarithromycin-ethambutol therapy for Mycobacterium avium
394 complex septicemia in AIDS patients. European journal of clinical microbiology & infectious
395 diseases. 1999;18(1):16-22.
396 30. Gerecht WB, Henry NK, Hoffman WW, Muller SM, LaRusso NF, Rosenblatt JE, et al.
397 Prospective randomized comparison of mezlocillin therapy alone with combined ampicillin and

398 gentamicin therapy for patients with cholangitis. Archives of internal medicine.
399 1989;149(6):1279-84.
400 31. Gibson J, Date L, Joshua DE, Young GA, Wilson A, Benn R, et al. A randomised trial of
401 empirical antibiotic therapy in febrile neutropenic patients with hematological disorders:
402 ceftazidime versus azlocillin plus amikacin. Australian and New Zealand journal of medicine.
403 1989;19(5):417-25.
404 32. Haase DA, Harding GK, Thomson MJ, Kennedy JK, Urias BA, Ronald AR. Comparative trial
405 of norfloxacin and trimethoprim-sulfamethoxazole in the treatment of women with localized,
406 acute, symptomatic urinary tract infections and antimicrobial effect on periurethral and fecal
407 microflora. Antimicrobial agents and chemotherapy. 1984;26(4):481-4.
408 33. Harbarth S, von Dach E, Pagani L, Macedo-Vinas M, Huttner B, Olearo F, et al.
409 Randomized non-inferiority trial to compare trimethoprim/sulfamethoxazole plus rifampicin
410 versus linezolid for the treatment of MRSA infection. Journal of antimicrobial chemotherapy.
411 2015;70(1):264-72.
412 34. Hodson ME, Roberts CM, Butland RJ, Smith MJ, Batten JC. Oral ciprofloxacin compared
413 with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with
414 cystic fibrosis. Lancet (london, england). 1987;1(8527):235-7.
415 35. Hoepelman IM, Rozenberg-Arska M, Verhoef J. Comparative study of ceftriaxone
416 monotherapy versus a combination regimen of cefuroxime plus gentamicin for treatment of
417 serious bacterial infections: the efficacy, safety and effect on fecal flora. Chemotherapy. 1988;34
418 Suppl 1:21-9.
419 36. Hultén K, Jaup B, Stenquist B, Engstrand L. Combination treatment with ranitidine is
420 highly efficient against Helicobacter pylori despite negative impact of macrolide resistance.
421 Helicobacter. 1997;2(4):188-93.
422 37. Iravani A, Richard GA, Baer H, Fennell R. Comparative efficacy and safety of nalidixic acid
423 versus trimethoprim/sulfamethoxazole in treatment of acute urinary tract infections in college-
424 age women. Antimicrobial agents and chemotherapy. 1981;19(4):598-604.
425 38. Jacobs RF, Vats TS, Pappa KA, Chaudhary S, Kletzel M, Becton DL. Ceftazidime versus
426 ceftazidime plus tobramycin in febrile neutropenic children. Infection. 1993;21(4):223-8.
427 39. Jo JH, Harkins CP, Schwardt NH, Portillo JA, Zimmerman MD, Carter CL, et al. Alterations
428 of human skin microbiome and expansion of antimicrobial resistance after systemic antibiotics.
429 Sci Transl Med. 2021;13(625):eabd8077.
430 40. Macnab MF, Bohmer PD, Seager JR. Evaluation of the 3-drug combination, Rifater,
431 versus 4-drug therapy in the ambulatory treatment of tuberculosis in Cape Town. South African
432 medical journal. 1994;84(6):325-8.
433 41. Markowitz N, Quinn EL, Saravolatz LD. Trimethoprim-sulfamethoxazole compared with
434 vancomycin for the treatment of Staphylococcus aureus infection. Annals of internal medicine.
435 1992;117(5):390-8.
436 42. Mavromanolakis E, Maraki S, Samonis G, Tselentis Y, Cranidis A. Effect of norfloxacin,
437 trimethoprim-sulfamethoxazole and nitrofurantoin on fecal flora of women with recurrent
438 urinary tract infections. Journal of chemotherapy (Florence, Italy). 1997;9(3):203-7.
439 43. May T, Brel F, Beuscart C, Vincent V, Perronne C, Doco-Lecompte T, et al. Comparison of
440 combination therapy regimens for treatment of human immunodeficiency virus-infected
441 patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium
442 Group. Agence Nationale de Recherche sur le Sida. Clinical infectious diseases. 1997;25(3):621-
443 9.

44. McCarty JM, Tilden SJ, Black P, Craft JC, Blumer J, Waring W, et al. Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis. Pediatric pulmonology. 1988;4(4):201-4.
45. Menon R, Roberts FE, Barr KW, Howard H, Lord VL, Hegarty MA, et al. Comparison of a slow-release trimethoprim with co-trimoxazole: efficacy and selection of resistance in the Enterobacteriaceae. Journal of antimicrobial chemotherapy. 1986;18(3):415-20.
46. Miehlke S, Meining A, Lehn N, Höchter W, Weingart J, Simon T, et al. Comparison of omeprazole, metronidazole and clarithromycin with omeprazole/amoxicillin dual-therapy for the cure of Helicobacter pylori infection. Digestion. 1998;59(6):646-50.
47. Parras F, Guerrero MC, Bouza E, Blázquez MJ, Moreno S, Menarguez MC, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrobial agents and chemotherapy. 1995;39(1):175-9.
48. Parry MF, Neu HC, Merlino M, Gaerlan PF, Ores CN, Denning CR. Treatment of pulmonary infections in patients with cystic fibrosis: a comparative study of ticarcillin and gentamicin. J Pediatr. 1977;90(1):144-8.
49. Parry CM, Ho VA, Phuong le T, Bay PV, Lanh MN, Tung le T, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrobial agents and chemotherapy. 2007;51(3):819-25.
50. Paul M, Bishara J, Yahav D, Goldberg E, Neuberger A, Ghanem-Zoubi N, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by meticillin resistant Staphylococcus aureus: randomised controlled trial. BMJ (Clinical research ed). 2015;350:h2219.
51. Pogue JM, Rybak MJ, Stamper K, Marchaim D, Thamlikitkul V, Carmeli Y, et al. Emergence of Colistin Resistance in the OVERCOME Trial: Impact of Combination Therapy with Meropenem. Open Forum Infectious Diseases. 2021;8(SUPPL 1):S418-S9.
52. Pujol M, Miró JM, Shaw E, Aguado JM, San-Juan R, Puig-Asensio M, et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis. 2021;72(9):1517-25.
53. Rubinstein E, Lode H, Grassi C, Castelo A, Ward K, Alanko K, et al. Ceftazidime monotherapy vs. Ceftriaxone/tobramycin for serious hospital- acquired gram-negative infections. Clinical Infectious Diseases. 1995;20(5):1217-28.
54. Schaeffer AJ, Flynn S, Jones J. Comparison of cinoxacin and trimethoprim-sulfamethoxazole in the treatment of urinary tract infections. Journal of urology. 1981;125(6):825-7.
55. Schaeffer AJ, Sisney GA. Efficacy of norfloxacin in urinary tract infection biological effects on vaginal and fecal flora. Journal of urology. 1985;133(4):628-30.
56. Smith AL, Doershuk C, Goldmann D, Gore E, Hilman B, Marks M, et al. Comparison of a β-lactam alone versus β-lactam and an aminoglycoside for pulmonary exacerbation in cystic fibrosis. Journal of Pediatrics. 1999;134(4):413-21.
57. Stack WA, Knifton A, Thirlwell D, Cockayne A, Jenkins D, Hawkey CJ, et al. Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. American journal of gastroenterology. 1998;93(10):1909-13.

58. Walsh TJ, Standiford HC, Reboli AC, John JF, Mulligan ME, Ribner BS, et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrobial agents and chemotherapy. 1993;37(6):1334-42.
59. Winston DJ, Ho WG, Nakao SL, Gale RP, Champlin RE. Norfloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. Am J Med. 1986;80(5):884-90.
60. Winston DJ, Ho WG, Bruckner DA, Gale RP, Champlin RE. Ofloxacin versus vancomycin/polymyxin for prevention of infections in granulocytopenic patients. American journal of medicine. 1990;88(1):36-42.
61. Wurzer H, Rodrigo L, Stamler D, Archambault A, Rokkas T, Skandalis N, et al. Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. Alimentary pharmacology & therapeutics. 1997;11(5):943-52.
62. Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet.
63. Joshi LT. The G7 Summit 2021: time for our world leaders to step up to the challenge of antimicrobial resistance. Access Microbiology. 2021;3(12).
64. Kerantzas Christopher A, Jacobs William R, Rubin Eric J, Collier RJ. Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application. mBio.8(2):e01586-16.
65. Fish DN, Piscitelli SC, Danziger LH. Development of resistance during antimicrobial therapy: a review of antibiotic classes and patient characteristics in 173 studies. Pharmacotherapy. 1995;15(3):279-91.
66. Hernán MA, Wang W, Leaf DE. Target Trial Emulation: A Framework for Causal Inference From Observational Data. JAMA. 2022;328(24):2446-7.
67. Hernán MA. Methods of Public Health Research — Strengthening Causal Inference from Observational Data. New England Journal of Medicine. 2021;385(15):1345-8.
68. Schulz KF, Altman DG, Moher D, for the CG. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLOS Medicine. 2010;7(3):e1000251.
69. Bramer WM, Giustini D, de Jonge GB, Holland L, Bekhuis T. De-duplication of database search results for systematic reviews in EndNote. J Med Libr Assoc. 2016;104(3):240-3.
70. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Systematic Reviews. 2021;10(1):89.
71. Jackson D, Law M, Stijnen T, Viechtbauer W, White IR. A comparison of seven random-effects models for meta-analyses that estimate the summary odds ratio. Stat Med. 2018;37(7):1059-85.
72. Deeks JJ, Higgins JPT, Altman DG. Analysing Data and Undertaking Meta-Analyses. Chichester, UK: John Wiley & Sons, Ltd; 2008. p. 243-96.
73. Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.
74. Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. Journal of Statistical Software. 2010;36(3):1 - 48.
75. Bartoń K. MuMIn: Multi-Model Inference. 2020.

Figures and Tables



Figure 1. Study selection



Figure 2. Measuring antibiotic resistance is not a current main objective of RCTs. A) Distribution of the publishing year of included studies, where n indicates the number of studies, and the red vertical line the median of the distribution. B) Calculated power of included studies to detect an odds ratio of 0.5. The power calculations were based on equal treatment arm sizes. For the calculations the treatment arm with the higher number of patients of the respective studies was used.



Figure 3. Forest plot of acquisition of bacterial resistance stratified by the reason antibiotics were administered. The coloring indicates the number of antibiotics that were compared in each study. A) The overall pooled LOR of all included studies. B) The pooled LOR of studies with at least one antibiotic in common in the treatment arms. UTI stands for urinary tract infection, MRSA for methicillin-resistant Staphylococcus aureus, MAC for Mycobacterium avium complex, and BSI for blood stream infection.

Table 1. Overview of the 42 RCTs or quasi-RCTs included in the systematic review and meta-analysis. The underlined antibiotics indicate that resistance measurements were made for this antibiotic, reported and extractable from the studies. Resistance outcome definitions marked with (*) indicate that the definition was not specifically provided by the study itself but states our justification for extraction.

Study	Type of Study	Focused pathogen/ Reason for antibiotic treatment	Objective(s)	Antibiotics used in study arms		Explicit Definition of Resistance Outcome	Secondary Outcomes extracted
				Less antibiotics	More Antibiotics		
Bender et al. (1979)(20)	RCT	Infection prophylaxis for patients with acute leukemia or malignant lymphomas receiving remission induction chemotherapy	Tolerance, suppression of microbial flora, protection against colonisation and infection	Gentamicin	Gentamicin, and vancomycin	no	All-cause mortality
Black et al. (1982)(21)	RCT	enterotoxigenic *Escherichia coli* (ETEC)	Compare two treatments options against ECET.	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	-
Chaisson et al. (1997)(22)	RCT	MAC	Safety and activity	Clarithromycin, and ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality
Cometta et al. (1997)(23)	RCT	Nosocomial pneumonia, nosocomial	Clinical efficacy and tolerance, emergence of	Imipenem	Imipenem, and netilmicin	no	Mortality attributable to infection,

		sepsis, or severe diffuse peritonitis	resistance and risk of superinfection				treatment failure, treatment failure due to a change of resistance against the study drugs
Dawson et al. (2015)(24)	RCT	Mtb	Efficacy, and safety	Moxifloxacin, pretomanid, and pyrazinamide	Isoniazid, rifampicin, pyrazinamide, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Dekker et al. (1987)(25)	RCT	Prophylaxis for acute nonlymphocytic or lymphocytic leukemia	Efficacy of protecting against infections	Ciprofloxacin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, mortality attributable to infection, acquisition of resistance against non-administered antibiotics
Dickstein et al. (2019)(26)	RCT	Carbapenem resistant, colistin-susceptible, and gram-negative infections	Development of colistin resistance (secondary outcome of a clinical trial)	Colistin	Colistin, and meropenem	yes	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Dubé et al. (1997)(27)	RCT	MAC	Risk of recrudescent MAC bacteraemia, emergence of resistance to clarithromycin.	Clarithromycin, and clofazimine	Clarithromycin, clofazimine, and ethambutol	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Durante-Mangoni et al. (2013)(28)	RCT	Extensively drug resistant *Acinetobacter baumannii*	Mortality	Colistin	Colistin, and rifampicin	yes	All-cause mortality, mortality attributable to infection, treatment failure
Fournier et al. (1999)(29)	RCT	MAC	Efficacy and tolerance.	Clarithromycin, ethambutol	Clarithromycin, ethambutol, and clofazimine	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Gerecht et al. (1989)(30)	RCT	Cholangitis	Compare a single drug treatment to a two-drug treatment.	Mezlocillin	Ampicillin, and gentamicin	yes	All-cause mortality, treatment failure as reported in each study, treatment failure due to a change of resistance against the study drugs

Gibson et al. (1989)(31)	RCT	Febrile neutropenia	Efficacy and side effects	Ceftazidime	Azlocillin, and amikacin	no	All-cause mortality, mortality attributable to infection, proportion of patients with alterations of the prescribed treatment due to adverse events, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Haase et al. (1984)(32)	RCT	UTI	Efficacy, tolerance, and safety	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	Treatment failure, acquisition of resistance against non-administered antibiotics
Hartbarth et al. (2015)(33)	RCT	MRSA	Assess the non-inferiority of a multiple drug treatment in comparison of a single drug treatment.	Linezolid	Trimethoprim, sulfamethoxazole, and rifampicin	no	All-cause mortality, mortality attributable to infection, treatment failure
Hodson (1987)(34)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Compare an oral one drug treatment to an intravenous two drug treatment.	Ciprofloxacin	Azlocillin, and gentamicin	no	-
Hoepelman et al. (1988)(35)	RCT	Serious bacterial infections	Emergence of resistance of fecal flora	Ceftriaxone	Cefuroxime, and gentamicin	no	Proportion of patients with alterations of the prescribed treatment due to adverse events
Hultén et al. (1997)(36)	RCT	*H. pylori*	Antibacterial efficacy, emergence of clarithromycin resistance.	Clarithromycin	Clarithromycin, and lymecycline	no	-
Iravani et al. (1981)(37)	RCT	Acute UTI	Efficacy, treatment effects on fecal flora, resistance emergence in the infecting pathogen	Nalidixic acid	Trimethoprim, and sulfamethoxazole	no	-
Jacobs et al. (1993)(38)	RCT	Bacterial infections in neutropenic children	Efficacy and safety, tolerance, emergence of resistance and risk of superinfection	Ceftazidime	Ceftazidime, and tobramycin	yes	All-cause mortality, treatment failure, treatment failure due to a change of resistance against the study drugs

Jo et al. (2021)(39)	RCT	Determine impact of antibiotics on healthy skin microbiota	Investigate short and long term of the skin microbiome	Doxcycycline	Trimethoprim, and sulfamethoxazole	no	-
Macnab et al. (1994)(40)	Quasi-RCT	Mtb	Efficacy, primary drug resistance, bacteriological conversion rates, compliance, and side effects	Isoniazid, and rifampicin	Isoniazid, rifampicin, and ethambutol	no	Proportion of patients with alterations of the prescribed treatment due to adverse event
Markowitz et al. (1992)(41)	RCT	*S. aureus*	Efficacy and safety	Vancomycin	Trimethoprim, and sulfamethoxazole	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mavromanolakis et al. (1997)(42)	RCT	Recurrent UTIs	Effect on the aerobic bowel flora, frequency of resistant strains in the fecal flora during and after treatment.	Norfloxacin, or Nitrofurantoin	Trimethoprim, and sulfamethoxazole	no	-
May et al. (1997)(43)	RCT	MAC	Clinical and bacteriological efficacy, safety, tolerability	Clarithromycin, and clofazimine	Clarithromycin, rifabutin, and ethambutol	no	All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Mc Carty et al. (1988)(44)	RCT	Cystic fibrosis patients with *P. aeruginosa*	Safety, pharmacokinetics of a high-dose singe drug treatment, the effectiveness	Piperacillin	Piperacillin, and tobramycin	no	All-cause mortality, mortality attributable to infection
Menon et al. (1986)(45)	RCT	Acute UTI	Efficacy, selection of resistance in Enterobacteriaceae	Trimethoprim	Trimethoprim, and sulfamethoxazole	no	Acquisition of resistance against non-administered antibiotics
Miehlke et al. (1998)(46)	RCT	*H. pylori*	Effectiveness, tolerability	Amoxicillin	Clarithromycin, and metronidazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events

Parras et al. (1995)(47)	RCT	MRSA	Efficacy to eradicate, safety	Mupirocin	Sodium fusidate, trimethoprim, and sulfamethoxazole	no	All-cause mortality, proportion of patients with alterations of the prescribed treatment due to adverse events
Parry et al. (1977)(48)	Quasi-RCT	*Pulmonary infection*	Effectiveness, treatment failure, treatment success, frequency of ticarcillin resistant organisms, influence of resistance on disease development	Ticarcillin	Ticarcillin, and gentamicin	no	-
Parry et al. (2007)(49)	RCT	Multidrug resistant typhoid fever	Efficacy	Ofloxacin, or Azithromycin	Ofloxacin, and Azithromycin	no	Treatment failure
Paul et al. (2015)(50)	RCT	MRSA	Test whether a two-drug treatment is non-inferior to a two-drug treatment.	Vancomycin	Trimethoprim, and sulfamethoxazole	yes	All-cause mortality, treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Pogue et al. (2021)(51)	RCT	Gram negative resistant bloodstream infections or pneumonia	Assess superiority of a combination of colistin to monotherapy.	Colistin	Colistin, and meropenem	yes	All-cause mortality, treatment failure
Pujol et al. (2021)(52)	RCT	MRSA	Assess treatment success.	Daptomycin	Daptomycin, and fosfomycin		All-cause mortality, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Rubinstein et al. (1995)(53)	RCT	Gram-negative hospital acquired infections	Efficacy, safety	Ceftazidime	Ceftriaxone, and Tobramycin	yes	All-cause mortality, mortality attributable to infection, treatment failure, proportion of patients with alterations of the prescribed treatment due to adverse events
Schaeffer et al. (1981)(54)	RCT	UTI	Effectiveness, safety, incidence of resistance in faecal and vaginal flora	Cinoxacin	Trimethoprim, and sulfamethoxazole	no	Proportion of patients with alterations of the prescribed treatment due to adverse events

			before, and after treatment.				
Schaeffer et al. (1985)(55)	RCT	UTI	Effectiveness, safety, incidence of resistance in fecal and vaginal flora before, and after treatment.	Norfloxacin	Trimethoprim, and sulfamethoxazole	no	-
Smith et al. (1999)(56)	RCT	P. aeruginosa	Efficacy	Azlocillin	Azlocillin, and tobramycin	no	Acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Stack et al. (1998)(57)	RCT	*H. pylori*	Efficacy, safety	Clarithromycin	Clarithromycin, and metronidazole, or amoxycillin	no	-
Walsh et al. (1993)(58)	RCT	MRSA	Efficacy of eradication, emergence of resistance, safety	Novobiocin, and rifampicin	Rifampicin, trimethoprim, and sulfamethoxazole	yes	Treatment failure, acquisition of resistance against non-administered antibiotics, emergence of resistance against non-administered antibiotics
Winston et al. (1986)(59)	RCT	Prophylaxis for blood cancer patients	Efficacy and safety	Norfloxacin	Vancomycin, and polymyxin	no	Mortality attributable to infection
Winston et al. (1990)(60)	RCT	Prophylaxis for blood cancer patients	Efficacy and safety	Ofloxacin	Vancomycin, and polymyxin	no	-
Wurzer et al. (1997)(61)	RCT	*H. pylori*	Effectiveness, emergence of resistance.	Clarithromycin	Clarithromycin, and amoxycillin	no	-